Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research6

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research6

FiltersClear all

Status

Recruiting2
Active, not recruiting2
Terminated2

Study type

Interventional6

Phase

Phase 1/26
Phase 18
Phase 25
Phase 32
Not applicable2
Not reported2
Phase 2/31
Phase 41

Investigator

Gail J Roboz3
John Allan2
Ruben Niesvizky1

Department

Medicine6

Condition

Recurrence6
Leukemia, Myeloid, Acute12
Prostatic Neoplasms10
Neoplasms9
Multiple Myeloma6

Intervention type

Drug5
Biological1
Combination product1

Sponsor type

Industry6

Start date

Has results posted2

Phase 1/2×Recurrence×Clear all

Showing 1–6 of 6 studiesSort:

Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗
Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

FiltersClear all

Status

Recruiting2
Active, not recruiting2
Terminated2

Study type

Interventional6

Phase

Phase 1/26
Phase 18
Phase 25
Phase 32
Not applicable2
Not reported2
Phase 2/31
Phase 41

Investigator

Gail J Roboz3
John Allan2
Ruben Niesvizky1

Department

Medicine6

Condition

Recurrence6
Leukemia, Myeloid, Acute12
Prostatic Neoplasms10
Neoplasms9
Multiple Myeloma6

Intervention type

Drug5
Biological1
Combination product1

Sponsor type

Industry6

Start date

Has results posted2

Phase 1/2×Recurrence×Clear all

Showing 1–6 of 6 studiesSort:

Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗
Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Show all 50

Show fewer

Myelodysplastic Syndromes5
Neoplasm Metastasis5
Carcinoma, Non-Small-Cell Lung4
Colorectal Neoplasms4
Hematologic Neoplasms4
Melanoma4
Parkinson Disease4
Breast Neoplasms3
Leukemia3
Leukemia, Lymphocytic, Chronic, B-Cell3
Lymphoma, Non-Hodgkin3
Pancreatic Neoplasms3
Hematologic Diseases2
Lung Neoplasms2
Precursor Cell Lymphoblastic Leukemia-Lymphoma2
Primary Myelofibrosis2
Small Cell Lung Carcinoma2
Stomach Neoplasms2
Urogenital Neoplasms2
Acrocephalosyndactylia1
Adenocarcinoma1
Alzheimer Disease1
Anemia1
Anemia, Hemolytic1
Anemia, Hemolytic, Autoimmune1
Anemia, Sickle Cell1
Angelman Syndrome1
Antiphospholipid Syndrome1
Autoimmune Diseases1
Blood Coagulation Disorders1
Blood Coagulation Disorders, Inherited1
Bone Marrow Diseases1
Brain Neoplasms1
Breast Diseases1
Bronchial Neoplasms1
Burkitt Lymphoma1
Canavan Disease1
Carcinoma1
Carcinoma, Adenoid Cystic1
Carcinoma, Neuroendocrine1
Carcinoma, Small Cell1
Carcinoma, Transitional Cell1
Cholangiocarcinoma1
Coagulation Protein Disorders1
Colonic Neoplasms1

Ruben NiesvizkyPI

Intervention: Drug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mg
Dates: Oct 2016 – May 2024· Results posted
Sponsor: Celgene Corporation

Multiple Myeloma

Active, not recruitingInterventional · Phase 1/2NCT04086264 ↗

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Gail J RobozPI

Intervention: Drug: Azacitidine · Drug: IMGN632 · Drug: Venetoclax
Dates: Nov 2019 – Feb 2027 (est.)
Sponsor: AbbVie Inc.

Acute Myeloid Leukemia

RecruitingInterventional · Phase 1/2NCT04150497 ↗

Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

Gail J RobozPI

Intervention: Biological: UCART22 · Biological: CLLS52
Dates: Oct 2019 – Jun 2026 (est.)
Sponsor: Cellectis, Inc

B-cell Acute Lymphoblastic Leukemia

RecruitingInterventional · Phase 1/2NCT06634589 ↗

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

John AllanPI

Intervention: Drug: Tacabrutideg · Drug: Sonrotoclax · Drug: Zanubrutinib · Drug: Mosunetuzumab · Drug: Glofitamab · Drug: Obinutuzumab
Dates: Nov 2024 – Dec 2028 (est.)
Sponsor: BeiGene USA

B-cell MalignancyRelapsed CancerRefractory Cancer+1 more

TerminatedInterventional · Phase 1/2NCT03572634 ↗

A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)

John AllanPI

Intervention: Drug: TP-0903 · Combination product: TP-0903 and ibrutinib combination therapy
Dates: Jun 2019 – Jan 2020· Results posted
Sponsor: Tolero Pharmaceuticals Inc.

Chronic Lymphocytic LeukemiaCLLSLL+1 more

TerminatedInterventional · Phase 1/2NCT04113616 ↗

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Gail J RobozPI

Intervention: Drug: KRT-232 · Drug: Cytarabine · Drug: Decitabine
Dates: Sep 2019 – Sep 2023
Sponsor: Kartos Therapeutics, Inc.

Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

Browse

Browse

Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)